{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:12:26Z","timestamp":1791515546467,"version":"4.3.4"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.2169\/internalmedicine.1099-18","type":"journal-article","created":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T22:48:21Z","timestamp":1533854901000},"page":"3351-3355","source":"Crossref","is-referenced-by-count":43,"title":["First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan"],"prefix":"10.2169","volume":"57","author":[{"given":"Yasuaki","family":"Okuda","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Jichi Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 337: 898-909, 1977.","DOI":"10.1056\/NEJM199709253371306"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamada T. Serum Amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37: 37: 381-388, 1999.","DOI":"10.1515\/CCLM.1999.063"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Gillmore JD, Lovat L, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid protein. Lancet 358: 24-29, 2001.","DOI":"10.1016\/S0140-6736(00)05252-1"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70: 246-256, 1991.","DOI":"10.1097\/00005792-199107000-00002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356: 2361-2371, 2007.","DOI":"10.1056\/NEJMoa070265"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Asua DR, Costa R, Galvan JM, et al. Systemic AA amyloidosis: epidemiology, diagnosis and management. Clin Epidemiol 6: 369-377, 2014.","DOI":"10.2147\/CLEP.S39981"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lane T, Pinney JH, Gilbertoson JA, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid 24: 162-166, 2017.","DOI":"10.1080\/13506129.2017.1342235"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Migita K, Agematsu K. Clinical aspects of Familial Mediterranean fever. Jpn. J. Clin. Immunol 34: 355-360, 2011.","DOI":"10.2177\/jsci.34.355"},{"key":"9","unstructured":"9. Okuda Y, Takasugi K, Oyama T, et al. Amyloidosis in rheumatoid arthritis - clinical study of 124 histologically proven cases. Ryumachi 34: 936-946, 1994."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Westermark GT, Johnson KH, Westermark P, et al. Staining methods for identification of amyloid tissue. Methods Enzymol 309: 4-9, 1999.","DOI":"10.1016\/S0076-6879(99)09003-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 24: 137-143, 2014.","DOI":"10.3109\/14397595.2013.854048"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/23\/57_1099-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T04:53:51Z","timestamp":1543640031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/23\/57_1099-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":11,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1099-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}